Qu’avons-nous compris en 20 ans sur la polyradiculoneuropathie inflammatoire démyélinisante chronique ? [What have we learned about chronic inflammatory demyelinating polyradiculoneuropathyin the last twenty years ?]
Fiche du document
27 avril 2022
- doi: 10.53738/REVMED.2022.18.779.808
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2022.18.779.808
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35481506
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_B256E36DFA3E3
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
illnessCiter ce document
L. Magy et al., « Qu’avons-nous compris en 20 ans sur la polyradiculoneuropathie inflammatoire démyélinisante chronique ? [What have we learned about chronic inflammatory demyelinating polyradiculoneuropathyin the last twenty years ?] », Serveur académique Lausannois, ID : 10.53738/REVMED.2022.18.779.808
Métriques
Partage / Export
Résumé
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) has been widely described during the last quarter of the twentieth century. The last 20 years have seen decisive progress in its understanding. The diagnostic criteria have been simplified and the steps of the diagnostic process have been clarified. The phenotypic contours of the disease are now well known, as are the diagnostic pitfalls. From a pathophysiological point of view, the discovery of autoantibodies directed against nodal and paranodal proteins has been a major advance, although it concerns only a minority of patients. These discoveries have a major impact on the therapeutic management of these patients, often suffering from a very active form of the disease. The next 20 years will surely see a further deepening of knowledge about this fascinating disease.